{"id":2241,"date":"2026-10-20T19:47:46","date_gmt":"2026-10-20T19:47:46","guid":{"rendered":"https:\/\/chatscopeai.com\/news\/fda-finalizes-safety-filing-guidance-for-new-dietary-supplement\/"},"modified":"2026-10-20T19:47:48","modified_gmt":"2026-10-20T19:47:48","slug":"fda-finalizes-safety-filing-guidance-for-new-dietary-supplement","status":"publish","type":"post","link":"https:\/\/chatscopeai.com\/news\/fda-finalizes-safety-filing-guidance-for-new-dietary-supplement\/","title":{"rendered":"FDA Finalizes Safety Filing Guidance for New Dietary Supplement Ingredients"},"content":{"rendered":"\n<p class=\"wp-block-paragraph hsn-lede\">FDA finalized guidance on identity and safety details for new supplement ingredient filings, recommending one safety narrative; comments accepted any time.<\/p>\n<p class=\"wp-block-paragraph\"><strong>The US Food and Drug Administration (FDA) has issued final guidance on what supplement makers should tell it about new ingredients. Firms must still file at least 75 days before sale, and comments on the guidance are open at any time.<\/strong><\/p>\n<p class=\"wp-block-paragraph\">FDA announced the final guidance in a Federal Register notice on Oct. 20, 2026<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\" id=\"hsn-cite-1\">1<\/a><\/sup>. It covers the identity and safety information that makers and sellers should include in a new dietary ingredient notification, a safety filing sent to FDA before a new supplement ingredient goes on sale<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. FDA says it will keep finalizing other parts of its 2016 draft guidance on these filings<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\" id=\"hsn-cite-2\">2<\/a><\/sup>.<\/p>\n<div class=\"hsn-table\">\n<div class=\"pcrstb-wrap\"><table>\n<thead><tr><th>At a glance<\/th><th>Details<\/th><\/tr><\/thead>\n<tbody>\n<tr><td>What was published<\/td><td>Final guidance for industry, not a binding rule<\/td><\/tr>\n<tr><td>Published on<\/td><td>20 October 2026 (Federal Register)<\/td><\/tr>\n<tr><td>Who must comply<\/td><td>Makers and sellers of new dietary ingredients and supplements that contain them<\/td><\/tr>\n<tr><td>Feedback deadline \/ Effective date<\/td><td>No deadline: comments accepted at any time<\/td><\/tr>\n<tr><td>Final rules \/ Next milestone<\/td><td>FDA to finalize other sections of the 2016 draft guidance<\/td><\/tr>\n<\/tbody>\n<\/table><\/div>\n<\/div>\n<h2 class=\"wp-block-heading\">What is a new dietary ingredient notification?<\/h2>\n<p class=\"wp-block-paragraph\">Under US food and drug law, some supplement firms must notify FDA before they sell a product<sup class=\"hsn-cite\"><a href=\"#hsn-ref-3\" id=\"hsn-cite-3\">3<\/a><\/sup>. This applies to a new dietary ingredient (NDI) that has not been in the food supply as food<sup class=\"hsn-cite\"><a href=\"#hsn-ref-3\">3<\/a><\/sup>. It also applies to a supplement that contains such an ingredient<sup class=\"hsn-cite\"><a href=\"#hsn-ref-3\">3<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\">The firm must file the notification <strong>at least 75 days before<\/strong> selling the product across state lines<sup class=\"hsn-cite\"><a href=\"#hsn-ref-3\">3<\/a><\/sup>. The filing must explain why the firm concluded the product will reasonably be expected to be safe as intended<sup class=\"hsn-cite\"><a href=\"#hsn-ref-3\">3<\/a><\/sup>. FDA calls this process its <strong>only opportunity<\/strong> to check these ingredients before they reach consumers<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>.<\/p>\n<div class=\"hsn-table\">\n<div class=\"pcrstb-wrap\"><table>\n<thead><tr><th>Filing requirement<\/th><th>What the law requires<\/th><\/tr><\/thead>\n<tbody>\n<tr><td>Who files<\/td><td>Maker or seller of the NDI or the supplement containing it<sup class=\"hsn-cite\"><a href=\"#hsn-ref-3\">3<\/a><\/sup><\/td><\/tr>\n<tr><td>When<\/td><td>At least 75 days before interstate sale<sup class=\"hsn-cite\"><a href=\"#hsn-ref-3\">3<\/a><\/sup><\/td><\/tr>\n<tr><td>What it must show<\/td><td>The basis for concluding the product is reasonably expected to be safe<sup class=\"hsn-cite\"><a href=\"#hsn-ref-3\">3<\/a><\/sup><\/td><\/tr>\n<tr><td>Legal basis<\/td><td>Section 413(a)(2) of the Federal Food, Drug, and Cosmetic Act and 21 CFR 190.6<sup class=\"hsn-cite\"><a href=\"#hsn-ref-3\">3<\/a><\/sup><\/td><\/tr>\n<\/tbody>\n<\/table><\/div>\n<\/div>\n<h2 class=\"wp-block-heading\">What the new guidance covers<\/h2>\n<p class=\"wp-block-paragraph\">The guidance answers frequently asked questions about these filings<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. It sets out the identity and safety information firms should include<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>. It also says when FDA recommends submitting different types of studies<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\">The document finalizes three sections of the 2016 revised draft guidance<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. They cover:<\/p>\n<ul>\n<li>identity information about the ingredient and the supplement<\/li>\n<li>history of use or other evidence of safety<\/li>\n<li>a summary of the basis for the firm&#8217;s safety conclusion<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">What changes for supplement makers<\/h2>\n<p class=\"wp-block-paragraph\">The biggest practical change concerns how firms present safety data. FDA dropped references to a separate &quot;comprehensive safety profile&quot;<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. Instead, it recommends <strong>a single &quot;safety narrative&quot;<\/strong> for all filings, to ease the burden of submitting separate documents<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\">FDA also added detail on what the safety narrative should contain<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. It clarified when firms should submit extra evidence of safety and which types of studies it recommends<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. Other edits aim to make the text clearer<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\">The guidance reflects FDA&#8217;s current thinking and is <strong>not binding<\/strong> on FDA or the public<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. Firms may use another approach if it meets the law and regulations<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. The paperwork it describes is already approved under Office of Management and Budget (OMB) control number 0910-0330<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/p>\n<h2 class=\"wp-block-heading\">A guidance 15 years in the making<\/h2>\n<p class=\"wp-block-paragraph\">FDA first published a draft guidance on these filings on July 5, 2011<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. It received significant comments and issued a revised draft on Aug. 12, 2016<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. The comment period on that draft was extended to Dec. 12, 2016<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/p>\n<div class=\"hsn-table\">\n<div class=\"pcrstb-wrap\"><table>\n<thead><tr><th>Key date<\/th><th>What happens<\/th><\/tr><\/thead>\n<tbody>\n<tr><td>July 5, 2011<\/td><td>First draft guidance announced<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup><\/td><\/tr>\n<tr><td>Aug. 12, 2016<\/td><td>Revised draft guidance announced<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup><\/td><\/tr>\n<tr><td>Dec. 12, 2016<\/td><td>Extended comment deadline on the revised draft<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup><\/td><\/tr>\n<tr><td>Oct. 19, 2026<\/td><td>FDA announces the final guidance<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup><\/td><\/tr>\n<tr><td>Oct. 20, 2026<\/td><td>Notice published in the Federal Register<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup><\/td><\/tr>\n<\/tbody>\n<\/table><\/div>\n<\/div>\n<p class=\"wp-block-paragraph\">FDA chose to finalize separate sections of the 2016 draft one at a time<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>. The agency says this responds to public comments and makes the guidance easier to use<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>. It will mark on the 2016 draft which parts are now final<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>.<\/p>\n<h2 class=\"wp-block-heading\">How to comment and what comes next<\/h2>\n<p class=\"wp-block-paragraph\">Comments on the final guidance can be sent at any time<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>. They go to Regulations.gov under docket number <strong>FDA-2025-D-6501<\/strong><sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>. Written comments go to FDA&#8217;s Dockets Management Staff in Rockville, Maryland<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\">FDA&#8217;s Office of Dietary Supplement Programs handles questions about the filing process<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>. The agency says it continues to prioritize finalizing the remaining parts of the 2016 draft<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>.<\/p>\n<h2 class=\"wp-block-heading\">Key terms in plain words<\/h2>\n<div class=\"hsn-table\">\n<div class=\"pcrstb-wrap\"><table>\n<thead><tr><th>Term<\/th><th>Meaning<\/th><\/tr><\/thead>\n<tbody>\n<tr><td>New dietary ingredient (NDI)<\/td><td>A supplement ingredient not previously in the food supply as food<\/td><\/tr>\n<tr><td>NDI notification (NDIN)<\/td><td>The safety filing a firm sends FDA before selling a product with an NDI<\/td><\/tr>\n<tr><td>Safety narrative<\/td><td>One written account of the evidence that the ingredient is safe<\/td><\/tr>\n<tr><td>Guidance<\/td><td>FDA&#8217;s advice on how to meet the law, which is not itself binding<\/td><\/tr>\n<tr><td>Docket<\/td><td>The public file where FDA collects comments on a document<\/td><\/tr>\n<tr><td>Interstate commerce<\/td><td>Selling or shipping products across US state lines<\/td><\/tr>\n<\/tbody>\n<\/table><\/div>\n<\/div>\n<p class=\"wp-block-paragraph\">FDA&#8217;s next step is to finalize the remaining sections of its 2016 draft guidance<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>.<\/p>\n<h2 class=\"wp-block-heading hsn-refs-title\">Sources<\/h2>\n<ol class=\"hsn-refs\">\n<li id=\"hsn-ref-1\"><a class=\"hsn-refs__back\" href=\"#hsn-cite-1\" aria-label=\"Back to reference 1 in the text\">\u21a9<\/a> <a href=\"https:\/\/www.federalregister.gov\/documents\/2026\/10\/20\/2026-21453\/new-dietary-ingredient-ndi-notifications-and-related-issues-identity-and-safety-information-about\" rel=\"noopener\" target=\"_blank\">Federal Register\n       :: \n      New Dietary Ingredient (NDI) Notifications and Related Issues; Identity and Safety Information About the NDI: Guidance for Industry; Availability<\/a> <span class=\"hsn-refs__url\">https:\/\/www.federalregister.gov\/documents\/2026\/10\/20\/2026-21453\/new-dietary-ingredient-ndi-notifications-and-related-issues-identity-and-safety-information-about<\/span><\/li>\n<li id=\"hsn-ref-2\"><a class=\"hsn-refs__back\" href=\"#hsn-cite-2\" aria-label=\"Back to reference 2 in the text\">\u21a9<\/a> <a href=\"https:\/\/www.fda.gov\/food\/hfp-constituent-updates\/fda-issues-guidance-identity-and-safety-information-new-dietary-ingredient-notifications\" rel=\"noopener\" target=\"_blank\">FDA Issues Guidance on Identity and Safety Information for New Dietary Ingredient Notifications | FDA<\/a> <span class=\"hsn-refs__url\">https:\/\/www.fda.gov\/food\/hfp-constituent-updates\/fda-issues-guidance-identity-and-safety-information-new-dietary-ingredient-notifications<\/span><\/li>\n<li id=\"hsn-ref-3\"><a class=\"hsn-refs__back\" href=\"#hsn-cite-3\" aria-label=\"Back to reference 3 in the text\">\u21a9<\/a> <a href=\"https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-new-dietary-ingredient-ndi-notifications-and-related-issues-identity-and-safety\" rel=\"noopener\" target=\"_blank\">Guidance for Industry: New Dietary Ingredient (NDI) Notifications and Related Issues; Identity and Safety Information About the NDI | FDA<\/a> <span class=\"hsn-refs__url\">https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-new-dietary-ingredient-ndi-notifications-and-related-issues-identity-and-safety<\/span><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>FDA finalized guidance on identity and safety details for new supplement ingredient filings, recommending one safety narrative; comments accepted any time.<\/p>\n","protected":false},"author":1,"featured_media":2239,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","_regnews_id":"35871","_hsn_citations":"[{\"n\":1,\"url\":\"https:\/\/www.federalregister.gov\/documents\/2026\/10\/20\/2026-21453\/new-dietary-ingredient-ndi-notifications-and-related-issues-identity-and-safety-information-about\",\"label\":\"Federal Register\\n       :: \\n      New Dietary Ingredient (NDI) Notifications and Related Issues; Identity and Safety Information About the NDI: Guidance for Industry; Availability\"},{\"n\":2,\"url\":\"https:\/\/www.fda.gov\/food\/hfp-constituent-updates\/fda-issues-guidance-identity-and-safety-information-new-dietary-ingredient-notifications\",\"label\":\"FDA Issues Guidance on Identity and Safety Information for New Dietary Ingredient Notifications | FDA\"},{\"n\":3,\"url\":\"https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-new-dietary-ingredient-ndi-notifications-and-related-issues-identity-and-safety\",\"label\":\"Guidance for Industry: New Dietary Ingredient (NDI) Notifications and Related Issues; Identity and Safety Information About the NDI | FDA\"}]","_hsn_no_sources":"","_hsn_content_hash":"41cc33592c86ec95255bb28034f84e9f65f270bc:d60c583dbc12848a43741eaff8f31a2da6f50960","_yoast_wpseo_focuskw":"dietary supplements","footnotes":""},"categories":[58,34],"tags":[50],"class_list":["post-2241","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-americas","category-food-beverage","tag-united-states-of-america"],"_links":{"self":[{"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/posts\/2241","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/comments?post=2241"}],"version-history":[{"count":1,"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/posts\/2241\/revisions"}],"predecessor-version":[{"id":2243,"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/posts\/2241\/revisions\/2243"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/media\/2239"}],"wp:attachment":[{"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/media?parent=2241"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/categories?post=2241"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/tags?post=2241"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}